The dose of HALDOL Decanoate 50 or HALDOL Decanoate 100 should be expressed in terms of its haloperidol content. The starting dose of haloperidol decanoate should be based on the patient's age, clinical history, physical condition, and response to previous antipsychotic therapy. The preferred approach to determining the minimum effective dose is to begin with lower initial doses and to adjust the dose upward as needed. For patients previously maintained on low doses of antipsychotics (. up to the equivalent of 10 mg/day oral haloperidol), it is recommended that the initial dose of haloperidol decanoate be 10–15 times the previous daily dose in oral haloperidol equivalents; limited clinical experience suggests that lower initial doses may be adequate.
Respiratory depression: The most dangerous complication of opioid therapy is respiratory depression . A lot of people know that some drug addicts have been known to get pure heroin or fentanyl, and then die with the needle still in their arm because they fell asleep and didn't breathe. That happens because of a huge overdose in a patient who is not in pain. Pain is a potent stimulator of the respiratory center in the brain. So if a person has pain, and the doctor increases the dose of opioids carefully until the pain is controlled, and then stops raising the dosage, the patient will not get respiratory depression .
In the long-term study in subjects with schizoaffective disorder, the EPS during the 25-week open-label INVEGA SUSTENNA® treatment were hyperkinesia (%), parkinsonism (%), tremor (%), dyskinesia (%), and dystonia (%). During the 15-month double-blind treatment, the incidence of any EPS was similar to that of the placebo group (% and % respectively). The most commonly reported treatment-emergent EPS-related adverse events ( > 2%) in any treatment group in the double-blind phase of the study (INVEGA SUSTENNA® versus placebo) were hyperkinesia (% vs. %), parkinsonism (% vs. %), and tremor (% vs. %).